CIS Pharma AG products

Due to its fast and deadly nature, brain cancer glioblastoma, GBM, comprises a poor prognosis. Treatment options are limited, and recurrence is universal. The blood-brain barrier, BBB, excludes the vast majority of cancer therapeutics from the brain. Clinical evidence demonstrates that there is a clinically significant tumor burden with an intact BBB in all GBM.

Despite the advancements in therapies, cancer remains a significant health burden. Over 10 million cancer patients die every year. Especially aggressive forms of cancer with poor prognosis and high spread of metastasis remain an important challenge. CIS Pharma develops an antibody-radionuclide conjugate, ARC, a targeted treatment for cancer patients resistant to chemotherapy.